Technical analysis of Fractyl Health, Inc. (GUTS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Price Performance
| 1 month | -21.56% |
| 3 months | -34.46% |
| Year-to-date | -74.43% |
| 1 year | -42.15% |
52-Week Range
| 52-week High | $2.44 |
| 52-week Low | $0.38 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $0.72 |
| SMA 200 | $0.94 |
| Beta | 1.19 |
| 30-day Volatility (annualised) | 78.3% |
| Price vs SMA 50 | -21.5% |
| Price vs SMA 200 | -40.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.23 | |
| 2025-11 | $1.57 | +27.6% |
| 2025-12 | $2.20 | +40.1% |
| 2026-01 | $0.46 | -79.1% |
| 2026-02 | $0.47 | +2.0% |
| 2026-03 | $0.46 | -2.5% |
| 2026-04 | $0.64 | +39.3% |
| 2026-05 | $0.81 | +26.5% |
| 2026-06 | $0.79 | -1.5% |
| 2026-07 | $0.69 | -13.8% |
| 2026-08 | $0.71 | +3.8% |
| 2026-09 | $0.56 | -20.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $0.56 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -52.73 |
| EV / EBITDA | -1.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -36.48 |
| Current Ratio | 3.15 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.47 |